Zacks Investment Research downgraded shares of OBAGI MEDICAL (OMPI) from OUTPERFORM to NEUTRAL on September 04, 2012, with a target price of $14.70.
OBAGI MEDICAL PRODUCTS develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. Obagi's products are only available through physicians.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on OBAGI MEDICAL (OMPI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment